Monopar Therapeutics Inc. MNPR
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +7.69%
- 1 year
- -17.92%
- Open
- 71.36
- Prev close
- 71.91
- Mkt cap
- 472.00M
- Vol
- 197.76K
- Avg vol
- 175.31K
- EPS
- -2.20
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 69.35
- High
- 72.76
- Forward P/E
- -10.17
- Beta
- 1.10
- Short ratio
- 0.15
- Inst. own
- 24.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2024
- 50-d avg
- 17.85
- 200-d avg
- 7.12
- 1y target
- 27.33
News
-
1 month ago benzinga.com
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145
Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $128 to $145.
2 months ago defenseworld.net
Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head-To-Head Contrast
Regenicin (OTCMKTS:RGIN - Get Free Report) and Monopar Therapeutics (NASDAQ: MNPR - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies…
2 months ago globenewswire.com
Monopar Appoints Jeffrey D. Kent, M.D.
WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
2 months ago seekingalpha.com
Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'
Monopar Therapeutics (MNPR) remains a "Strong Buy," driven by exclusive license rights to ALXN1840 for Wilson disease and ongoing radiotherapeutic development. Completion of the rolling NDA for…
2 months ago benzinga.com
This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. STUB downgraded, MNPR neutral, BETR.
-
2 months ago benzinga.com
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128
Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $125 to $128.
-
2 months ago benzinga.com
Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119
Cantor Fitzgerald analyst Kristen Kluska downgrades Monopar Therapeutics (NASDAQ:MNPR) from Overweight to Neutral and raises the price target from $109 to $119.
2 months ago 247wallst.com
Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More
Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upgrading others, and the gap between winners and losers tells a story about where smart money is…
-
2 months ago benzinga.com
BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133
BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $117 to $133.
-
2 months ago benzinga.com
Monopar Therapeutics Q2 EPS $(0.62) Misses $(0.56) Estimate
Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.56) by 10.71 percent. This is a 77.14 percent decrease over losses…
2 months ago globenewswire.com
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
WILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments…
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $105 to $125.
-
3 months ago benzinga.com
Monopar Therapeutics Begins Rolling Submission Of FDA New Drug Application For ALXN1840 Albumin Tripartite Complex Activator To Treat Wilson Disease
The FDA has authorized Monopar to submit the NDA on a rolling basis, allowing completed sections of the application to be submitted and reviewed while the Company finalizes the remaining sections.…
3 months ago globenewswire.com
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
3 months ago globenewswire.com
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
WILMETTE, Ill., July 20, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
4 months ago seekingalpha.com
Monopar Therapeutics: ALXN1840's Bull Case Has Improved
Monopar Therapeutics has evolved from early radiopharma assets into a more concrete bet with ALXN1840 for rare diseases. ALXN1840 is their Wilson disease asset, which currently has a much clearer…
-
4 months ago benzinga.com
Monopar Says FDA Grants Rare Pediatric Disease Designation To ALXN1840, Late-Stage Candidate For Treatment Of Wilson Disease
Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced
4 months ago globenewswire.com
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
-
4 months ago benzinga.com
BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $117
BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $104 to $117.
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Monopar Therapeutics, Maintains $105 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $105 price target.
-
4 months ago benzinga.com
Monopar Therapeutics To Present New Analyses From Phase 3 FoCus Randomized Clinical Trial Of ALXN1840 At EAN 2026.
Key findings presented at EAN 2026:In the subset of patients with neurologic symptoms at baseline from the 2:1 randomized Phase 3 FoCus clinical trial (NCT03403205; n=207), ALXN1840 demonstrated…
4 months ago globenewswire.com
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular session. Atlantic International (NASDAQ:ATLN) stock rose 143.31% to $1.07. The market value of their…
4 months ago zacks.com
Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade
The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to an 88.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement…
5 months ago globenewswire.com
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
WILMETTE, Ill., June 01, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
-
5 months ago benzinga.com
Monopar Therapeutics Publishes Phase 2 Study Demonstrating ALXN1840 Improves Copper Balance In Patients With Wilson Disease
Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced
5 months ago globenewswire.com
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
WILMETTE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for…
5 months ago globenewswire.com
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
WILMETTE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for…
6 months ago globenewswire.com
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
WILMETTE, Ill. , April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
-
7 months ago benzinga.com
Monopar Therapeutics Q4 EPS $(0.61) Misses $(0.54) Estimate
Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.54) by 12.96 percent. This is a 72.65 percent increase over losses…
7 months ago globenewswire.com
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative…
7 months ago defenseworld.net
Monopar Therapeutics Inc. $MNPR Shares Acquired by Ally Bridge Group NY LLC
Ally Bridge Group NY LLC increased its position in shares of Monopar Therapeutics Inc. (NASDAQ: MNPR) by 86.6% in the undefined quarter, according to its most recent disclosure with the Securities…
8 months ago globenewswire.com
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical‐stage biopharmaceutical company developing innovative treatments…
-
10 months ago benzinga.com
The Year-End 2025 Biotech Rally And What It Means For 2026
The Year-End 2025 Biotech Rally And What It Means For 2026
10 months ago zacks.com
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.
11 months ago benzinga.com
This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
1 year ago benzinga.com
This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
1 year ago benzinga.com
This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
2 years ago benzinga.com
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
2 years ago benzinga.com
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
2 years ago benzinga.com
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results.
-
2 years ago benzinga.com
Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results.
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
2 years ago benzinga.com
Why StoneCo Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
StoneCo Ltd. (NASDAQ: STNE) shares rose in pre-market trading after the company reported upbeat results for its third quarter on Friday.
-
3 years ago benzinga.com
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 128 companies set new 52-week lows.